JPMorgan placed shares of Novo Nordisk (NVO) on “Positive Catalyst Watch” ahead of the CagriSema REDEFINE 1 obesity data. The firm’s analysis suggests CagriSema is likely to deliver 25% weight loss ...
Europe's main stock index logged its best day in six weeks on Monday, with defence stocks in the lead on prospects of higher ...
Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...
Hosted on MSN7h
Is Viking Therapeutics a Buy on the Dip?The biotech company presented solid data for a candidate that could eventually rival blockbuster weight loss drugs from big ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...
Evotec sees a 13.3% stock rise amid reports of Triton Partners eyeing a potential buyout after acquiring a 9.99% stake in the ...
With the rise in the popularity of weight loss drugs like ‘Wegovy’ and ‘Ozempic,’ we’re learning a counterfeit market has ...
Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...
SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...
Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...
A study reveals racial and ethnic disparities in access to Novo Nordisk's diabetes and weight loss drugs among U.S. military veterans. Black, Asian, and Native American patients are less likely to ...
U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for diabetes and weight loss, according to a review of patient data published on Monday, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback